{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:45:26Z","timestamp":1761763526780},"reference-count":41,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2001,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The concept that neuroendocrine cells detected within prostate adenocarcinoma produce paracrine factors, that may exert a proliferative effect on exocrine prostate tumor cells, provides a rationale for the use of somatostatin analogs with the aim to counteract or delay the tumor progression. This study was designed to provide preliminary information on the effect of the administration of a long\u2010acting somatostatin analog, lanreotide, on plasma levels of chromogranin A (CgA). Secondary aims were the evaluation of changes in circulating prostate\u2010specific antigen (PSA) and insulin\u2010like growth factor\u20101 (IGF\u20101).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Lanreotide (Ipstyl 30 mg; Ipsen, Milan, Italy) was administered intramuscularly every 14 days for 2 months to nine heavily pretreated prostate cancer patients with hormone refractory disease. All patients had, at baseline conditions, CgA values above the normal range. Androgen deprivation was maintained during the study period, while other concomitant antineoplastic treatments were not allowed. Serum PSA levels and plasma CgA and IGF\u20101 values were measured every week.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Lanreotide treatment was very well tolerated and no patient experienced major toxicity. Plasma CgA values at baseline: mean 109 U\/liter, standard deviation\u2009\u00b1\u200985 decreased significantly after treatment as follows: 42 U\/liter, \u00b1\u200917.8; 27.2 U\/liter\u2009\u00b1\u200913.6; 31.4 U\/liter, \u00b1\u200917.8 and 27.6 U\/liter, \u00b1\u200917.0; after 7, 14, 21, and 28 days, respectively (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01, Friedman ANOVA). Serum PSA did not change. Baseline IGF\u20101 was found to be above the detection limit in four cases, all of them showing a decrease after lanreotide.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Lanreotide administration to prostate cancer patients induces a decrease in plasma CgA and IGF\u20101 levels, without any influence on serum PSA values. <jats:italic>Prostate<\/jats:italic> 47:205\u2013211, 2001. \u00a9 2001 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.1064","type":"journal-article","created":{"date-parts":[[2002,9,10]],"date-time":"2002-09-10T23:06:08Z","timestamp":1031699168000},"page":"205-211","source":"Crossref","is-referenced-by-count":21,"title":["Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin\u2010A, prostate\u2010specific antigen, and insulin\u2010like growth factor\u20101 in advanced prostate cancer patients"],"prefix":"10.1002","volume":"47","author":[{"given":"Alfredo","family":"Berruti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Dogliotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Tarabuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirella","family":"Torta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Mari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Gorzegno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,5]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(1998)8 <43::AID-PROS8>3.0.CO;2-H"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(1998)8 <52::AID-PROS9>3.0.CO;2-I"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<357::AID-CNCR27>3.0.CO;2-U"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(1998)8 <74::AID-PROS11>3.0.CO;2-O"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(1998)8 <18::AID-PROS4>3.0.CO;2-C"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990190202"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(95)90033-0"},{"key":"e_1_2_1_10_2","first-page":"3237","article-title":"Chromogranin A, the major cathecolamine storage vesicle soluble protein","volume":"259","author":"O'Connor DT","year":"1984","journal-title":"J Biol Chem"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198605013141803"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00062-4"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000601)88:11<2590::AID-CNCR23>3.0.CO;2-D"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66261-X"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65203-0"},{"issue":"5","key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1210\/endo.140.5.6721","article-title":"Evidence that insuline\u2010like growth factor I and growth hormone are required for prostate gland development","volume":"140","author":"Ruan W","year":"1999","journal-title":"Endocrinology"},{"key":"e_1_2_1_17_2","first-page":"64","article-title":"Growth hormone and prostate cancer: guilty by association","volume":"22","author":"Grimberg A","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90073-6"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601253340408"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.2.279"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000201401"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008205415035"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70062-1"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950415)75:8<2159::AID-CNCR2820750820>3.0.CO;2-O"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(87)90107-X"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(87)90073-7"},{"key":"e_1_2_1_27_2","first-page":"217","volume-title":"Use of analogues of LHRH and somatostatin for the treatment of hormone dependent cancers. Hormones, cell biology, and cancer: perspectives and potentials","author":"Redding TW","year":"1988"},{"key":"e_1_2_1_28_2","first-page":"8977","article-title":"Oncological applications of somatostatin analogues","volume":"48","author":"Schally AV","year":"1988","journal-title":"Cancer Res"},{"key":"e_1_2_1_29_2","first-page":"4851","article-title":"Partial inhibition of the growth of transplanted rat prostate tumors with the long\u2010acting somatostatin analogue sandostatin (SMS 201\u2013995)","volume":"48","author":"Siegel RA","year":"1988","journal-title":"Cancer Res"},{"key":"e_1_2_1_30_2","first-page":"2646","article-title":"Treatment of R\u20103327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration","volume":"50","author":"Bodgen AE","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<188::AID-CNCR26>3.0.CO;2-3"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.8.2566"},{"issue":"23","key":"e_1_2_1_33_2","first-page":"5805s","article-title":"Metastatic hormone\u2010refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111\u2010In]\u2010labeled DTPA\u2010d\u2010[Phe]\u2010Octreotide scintigraphy","volume":"55","author":"Nilsson S","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_1_34_2","first-page":"513","article-title":"[111In\u2010DTPA\u2010D\u2010Phe1]\u2010Octreotide scintigraphy in patients with hormone\u2010refractory prostatic adenocarcinoma can predict therapy outcome with Octreotide treatment: a pilot study","volume":"18","author":"Kalkner KM","year":"1998","journal-title":"Anticancer Res"},{"key":"e_1_2_1_35_2","first-page":"2731","article-title":"SMS 201\u2013995 in the treatment of refractory prostatic carcinoma","volume":"14","author":"Logothetis CJ","year":"1994","journal-title":"Anticancer Res"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00163570"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685857"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008238422151"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"issue":"4","key":"e_1_2_1_40_2","first-page":"206","article-title":"Prostate\u2010specific antigen and other serum markers: current concepts from the World Health Organization Second International Consultation on prostate cancer","volume":"17","author":"Brawer MK","year":"1999","journal-title":"Semin Urol Oncol"},{"key":"e_1_2_1_41_2","first-page":"48","article-title":"Determinants of circulating insulin\u2010like growth factor 1","volume":"22","author":"Hall K","year":"1999","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"e_1_2_1_42_2","first-page":"889","article-title":"Somatostatin analogue SMS 201\u2013995 lowers IGF\u2010I levels in patients with potentially IGF\u2010I dependent cancers","volume":"9","author":"Pollak M","year":"1989","journal-title":"Anticancer Res"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.1064","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.1064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T09:11:12Z","timestamp":1700298672000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.1064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,5,15]]}},"alternative-id":["10.1002\/pros.1064"],"URL":"https:\/\/doi.org\/10.1002\/pros.1064","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}